Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis

state of the art

Claudia Fabiani, Antonio Vitale, Giuseppe Lopalco, Florenzo Iannone, Bruno Frediani, Luca Cantarini

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The purpose of the present review was to provide a comprehensive picture of the efficacy of the different tumor necrosis factor (TNF)-α inhibiting agents in the treatment of acute anterior uveitis (AAU), the most common extra-articular manifestation of ankylosing spondylitis (AS). AS related, AAU may lead to severe visual impairment, due to frequent flare recurrences, anterior, and posterior segment complications and traditional treatment side effects. Considerably higher levels of tumor necrosis factor (TNF) have been assessed in the aqueous humor and inflamed joints of patients with AS. Anti-TNF drugs have shown efficacy in preventing relapses of rheumatological manifestations of spondyloarthropathies. Several studies have underlined the sustained efficacy of the monoclonal anti-TNF antibodies also in reducing the recurrence of anterior chamber flares in patients with AS-related AAU. On the other hand, retrospective studies and observational reports have indicated lower effectiveness and some paradoxical occurrence of uveitis following treatment with the soluble receptor agent etanercept. Growing evidence suggests that a prophylactic strategy could be advocated in subjects with frequent and recalcitrant attacks of AS-AAU. In this regard, the administration of monoclonal anti-TNF antibodies such as adalimumab (ADA) has been shown to significantly reduce the rate of AAU recurrences. Indeed, during ADA treatment about 90 % of patients have shown to remain completely free of attacks for the entire follow-up period, in most studies. Further studies are needed to confirm the long-term efficacy of TNF inhibitors in AS related AAU and also their role in preventing ocular complications and visual impairment.

Original languageEnglish
Pages (from-to)2631-2638
Number of pages8
JournalClinical Rheumatology
Volume35
Issue number11
DOIs
Publication statusPublished - Nov 1 2016

Fingerprint

Anterior Uveitis
Ankylosing Spondylitis
Tumor Necrosis Factor-alpha
Recurrence
Vision Disorders
Joints
Spondylarthropathies
Antibodies
Aqueous Humor
Uveitis
Anterior Chamber
Therapeutics
Retrospective Studies
Pharmaceutical Preparations

Keywords

  • Ankylosing spondylitis
  • Anterior uveitis
  • Biologics
  • Spondyloarthritis
  • TNF inhibitors

ASJC Scopus subject areas

  • Rheumatology

Cite this

Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis : state of the art. / Fabiani, Claudia; Vitale, Antonio; Lopalco, Giuseppe; Iannone, Florenzo; Frediani, Bruno; Cantarini, Luca.

In: Clinical Rheumatology, Vol. 35, No. 11, 01.11.2016, p. 2631-2638.

Research output: Contribution to journalArticle

Fabiani, Claudia ; Vitale, Antonio ; Lopalco, Giuseppe ; Iannone, Florenzo ; Frediani, Bruno ; Cantarini, Luca. / Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis : state of the art. In: Clinical Rheumatology. 2016 ; Vol. 35, No. 11. pp. 2631-2638.
@article{a33b81163aff41dd8df5d89344882bad,
title = "Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art",
abstract = "The purpose of the present review was to provide a comprehensive picture of the efficacy of the different tumor necrosis factor (TNF)-α inhibiting agents in the treatment of acute anterior uveitis (AAU), the most common extra-articular manifestation of ankylosing spondylitis (AS). AS related, AAU may lead to severe visual impairment, due to frequent flare recurrences, anterior, and posterior segment complications and traditional treatment side effects. Considerably higher levels of tumor necrosis factor (TNF) have been assessed in the aqueous humor and inflamed joints of patients with AS. Anti-TNF drugs have shown efficacy in preventing relapses of rheumatological manifestations of spondyloarthropathies. Several studies have underlined the sustained efficacy of the monoclonal anti-TNF antibodies also in reducing the recurrence of anterior chamber flares in patients with AS-related AAU. On the other hand, retrospective studies and observational reports have indicated lower effectiveness and some paradoxical occurrence of uveitis following treatment with the soluble receptor agent etanercept. Growing evidence suggests that a prophylactic strategy could be advocated in subjects with frequent and recalcitrant attacks of AS-AAU. In this regard, the administration of monoclonal anti-TNF antibodies such as adalimumab (ADA) has been shown to significantly reduce the rate of AAU recurrences. Indeed, during ADA treatment about 90 {\%} of patients have shown to remain completely free of attacks for the entire follow-up period, in most studies. Further studies are needed to confirm the long-term efficacy of TNF inhibitors in AS related AAU and also their role in preventing ocular complications and visual impairment.",
keywords = "Ankylosing spondylitis, Anterior uveitis, Biologics, Spondyloarthritis, TNF inhibitors",
author = "Claudia Fabiani and Antonio Vitale and Giuseppe Lopalco and Florenzo Iannone and Bruno Frediani and Luca Cantarini",
year = "2016",
month = "11",
day = "1",
doi = "10.1007/s10067-016-3426-3",
language = "English",
volume = "35",
pages = "2631--2638",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer London",
number = "11",

}

TY - JOUR

T1 - Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis

T2 - state of the art

AU - Fabiani, Claudia

AU - Vitale, Antonio

AU - Lopalco, Giuseppe

AU - Iannone, Florenzo

AU - Frediani, Bruno

AU - Cantarini, Luca

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The purpose of the present review was to provide a comprehensive picture of the efficacy of the different tumor necrosis factor (TNF)-α inhibiting agents in the treatment of acute anterior uveitis (AAU), the most common extra-articular manifestation of ankylosing spondylitis (AS). AS related, AAU may lead to severe visual impairment, due to frequent flare recurrences, anterior, and posterior segment complications and traditional treatment side effects. Considerably higher levels of tumor necrosis factor (TNF) have been assessed in the aqueous humor and inflamed joints of patients with AS. Anti-TNF drugs have shown efficacy in preventing relapses of rheumatological manifestations of spondyloarthropathies. Several studies have underlined the sustained efficacy of the monoclonal anti-TNF antibodies also in reducing the recurrence of anterior chamber flares in patients with AS-related AAU. On the other hand, retrospective studies and observational reports have indicated lower effectiveness and some paradoxical occurrence of uveitis following treatment with the soluble receptor agent etanercept. Growing evidence suggests that a prophylactic strategy could be advocated in subjects with frequent and recalcitrant attacks of AS-AAU. In this regard, the administration of monoclonal anti-TNF antibodies such as adalimumab (ADA) has been shown to significantly reduce the rate of AAU recurrences. Indeed, during ADA treatment about 90 % of patients have shown to remain completely free of attacks for the entire follow-up period, in most studies. Further studies are needed to confirm the long-term efficacy of TNF inhibitors in AS related AAU and also their role in preventing ocular complications and visual impairment.

AB - The purpose of the present review was to provide a comprehensive picture of the efficacy of the different tumor necrosis factor (TNF)-α inhibiting agents in the treatment of acute anterior uveitis (AAU), the most common extra-articular manifestation of ankylosing spondylitis (AS). AS related, AAU may lead to severe visual impairment, due to frequent flare recurrences, anterior, and posterior segment complications and traditional treatment side effects. Considerably higher levels of tumor necrosis factor (TNF) have been assessed in the aqueous humor and inflamed joints of patients with AS. Anti-TNF drugs have shown efficacy in preventing relapses of rheumatological manifestations of spondyloarthropathies. Several studies have underlined the sustained efficacy of the monoclonal anti-TNF antibodies also in reducing the recurrence of anterior chamber flares in patients with AS-related AAU. On the other hand, retrospective studies and observational reports have indicated lower effectiveness and some paradoxical occurrence of uveitis following treatment with the soluble receptor agent etanercept. Growing evidence suggests that a prophylactic strategy could be advocated in subjects with frequent and recalcitrant attacks of AS-AAU. In this regard, the administration of monoclonal anti-TNF antibodies such as adalimumab (ADA) has been shown to significantly reduce the rate of AAU recurrences. Indeed, during ADA treatment about 90 % of patients have shown to remain completely free of attacks for the entire follow-up period, in most studies. Further studies are needed to confirm the long-term efficacy of TNF inhibitors in AS related AAU and also their role in preventing ocular complications and visual impairment.

KW - Ankylosing spondylitis

KW - Anterior uveitis

KW - Biologics

KW - Spondyloarthritis

KW - TNF inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84989177906&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84989177906&partnerID=8YFLogxK

U2 - 10.1007/s10067-016-3426-3

DO - 10.1007/s10067-016-3426-3

M3 - Article

VL - 35

SP - 2631

EP - 2638

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 11

ER -